Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Nguyen on the Role of Radiation Therapy in High-Risk Prostate Cancer

September 2nd 2020

Paul L. Nguyen, MD, discusses the role of radiation therapy in high-risk prostate cancer.

Rucaparib Shows Meaningful Antitumor Activity in BRCA1/2-Mutated mCRPC

August 28th 2020

Rucaparib (Rubraca) demonstrated encouraging antitumor activity with a manageable safety profile in patients with BRCA-mutant metastatic castration-resistant prostate cancer.

Increased Access to Germline Testing Needed in Prostate Cancer

August 27th 2020

Germline genetic testing is a key component of prostate cancer treatment, and broader testing criteria combined with reduced barriers to these tests could result in better informed care, including preventive surveillance, according to data from a recent study.

Dr. Trinh on the Challenges of the COVID-19 Pandemic in Prostate Cancer

August 26th 2020

Quoc-Dien Trinh, MD, discusses the challenges of the novel coronavirus disease 2019 pandemic in prostate cancer.

Dr. Trinh on How COVID-19 Has Impacted Surgical Decisions in Prostate Cancer

August 26th 2020

Quoc-Dien Trinh, MD, discusses surgical considerations for patients with prostate cancer in light of the novel coronavirus disease pandemic.

COVID-19 Presents New Challenges in the Rapidly Evolving Prostate Cancer Paradigm

August 21st 2020

Bradley A. McGregor, MD, sheds light on recently approved agents, as well as a multitude of novel therapies on the horizon, that appear to spell out a promising future for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

FDA Halts Phase 1 Trial With P-PSMA-101 in mCRPC Following Patient Death

August 18th 2020

The FDA has placed a clinical hold on the phase 1 P-PSMA-101-001 trial examining the autologous CAR T-cell therapy P-PSMA-101 in patients with metastatic castration-resistant prostate cancer.

Taking a Tiered Approach to Prostate Cancer Surgery During the COVID-19 Pandemic

August 18th 2020

Quoc-Dien Trinh, MD, discusses the impact of the COVID-19 pandemic on prostate cancer treatment and factors that are considered to inform treatment decisions.

Cell-Free DNA Analysis Could Aid in Detection, Optimal Management of Resistant Metastatic Prostate Cancer

August 18th 2020

Cell-free DNA–based androgen receptor locus alterations and enhancers correlated with metastatic prostate cancers determined to be resistant to AR-targeted therapies.

Late LHRH Agonists Injections Cause Spike in Testosterone Levels in Prostate Cancer

August 17th 2020

Luteinizing hormone-releasing hormone agonists were found to often be administered later than the scheduled dosing used in patients with prostate cancer on pivotal clinical trials, leading to late testosterone values being greater than 20 ng/dL and the mean testosterone level almost doubling castration level.

Alternative Splicing, E7107 Compound Could Aid in Prostate Cancer Pathogenesis and Drug Development

August 17th 2020

In prostate cancer, investigators have revealed a link between disease progression and the severity of splicing dysregulation, as well as establishing intron retention as an indicator of prostate cancer stemness and aggressiveness.

Biomarker-Driven Monotherapy Enters mCRPC Paradigm

August 15th 2020

The PARP inhibitor olaparib is now available for patients with metastatic castration-resistant prostate cancer whose tumors harbor mutations in homologous recombination repair genes.

Antiandrogens Continue to Be Focus of Nonmetastatic CRPC Treatment

August 12th 2020

Atish D. Choudhury, MD, PhD, sheds light on the nonmetastatic castration-resistant prostate cancer treatment landscape and notable ongoing trials examining antiandrogens in different settings.

Stronger Racial and Ethnic Minority Presence Is Needed in Clinical Cancer Trials

August 12th 2020

Numerous analyses conducted over the past few years have underscored a serious issue in clinical cancer trials that needs to be addressed: a lack of racial and ethnic diversity among participants.

Radiation/ADT Use in High-Risk Prostate Cancer Can Be Personalized

August 12th 2020

Paul L. Nguyen, MD, discusses the role of radiation in high-risk prostate cancer and ongoing research efforts in the space.

Intense Neoadjuvant ADT Prior to Radical Prostatectomy Leads to Promising pCRs in High-Risk Prostate Cancer

August 11th 2020

Rana R. McKay, MD, discusses the benefit of intense neoadjuvant hormone therapy prior to radical prostatectomy in men with high-risk prostate cancer and next steps for research.

Study Explores Genomics of Race in Prostate Cancer

August 6th 2020

Although the genomic profiles of African American men with prostate cancer differ from those of European American men, new data show that the frequency of actionable mutations for which targeted therapies exist occurs at a comparable rate in both populations.

Dr. Gafita on Prognostic Models for Treatment With 177Lu-PSMA-617 in mCRPC

August 5th 2020

Andrei Gafita, MD, discusses key takeaways from a retrospective analysis evaluating lutetium-177 PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Dr. Shore on Challenges with ADT in Recurrent Prostate Cancer

August 4th 2020

Neal D. Shore, MD, FACS, discusses challenges with androgen deprivation therapy in recurrent prostate cancer.

Dr. Agarwal on the Safety Profile of Olaparib in HRR Gene-Mutant mCRPC

August 4th 2020

Neeraj Agarwal, MD, discusses the safety profile of olaparib in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.